[Accurate assessment of myocardial viability: complementation of Thallium-201 scintigraphy with a subsequent reinjection study]. 1992

L Bajnok, and J Varga, and A Sztankay
Debreceni Orvostudományi Egyetem, I. sz. Belgyógyászati Klinika.

Persistent myocardial thallium perfusion defects 3 to 4 hours after stress do not represent irreversible ischemia in every case. In many instances signs of reversibility show up 8-72 hours later or after rest reinjection. Authors performed additional investigations of redistribution in 64 patients with persistent defects. Rest reinjection was given to 11 patients and delayed redistribution was followed in the others. Persistent perfusion defects improved or disappeared in 13 percent of myocardial segments and 38 percent of patients. In 18% of segments late reverse redistribution was observed. The assessment of patients' state was significantly influenced by the results of the additional investigations in 19% of cases. Authors suggest that important information can be obtained about the viability of the myocardium by the extended studies even with the common planar method.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009202 Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). Myocardial Disease,Myocardial Diseases,Myocardial Diseases, Primary,Myocardial Diseases, Secondary,Myocardiopathies,Primary Myocardial Disease,Cardiomyopathies, Primary,Cardiomyopathies, Secondary,Primary Myocardial Diseases,Secondary Myocardial Diseases,Cardiomyopathy,Cardiomyopathy, Primary,Cardiomyopathy, Secondary,Disease, Myocardial,Disease, Primary Myocardial,Disease, Secondary Myocardial,Diseases, Myocardial,Diseases, Primary Myocardial,Diseases, Secondary Myocardial,Myocardial Disease, Primary,Myocardial Disease, Secondary,Myocardiopathy,Primary Cardiomyopathies,Primary Cardiomyopathy,Secondary Cardiomyopathies,Secondary Cardiomyopathy,Secondary Myocardial Disease
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D005260 Female Females
D006334 Heart Function Tests Examinations used to diagnose and treat heart conditions. Cardiac Function Tests,Cardiac Function Test,Function Test, Cardiac,Function Test, Heart,Function Tests, Cardiac,Function Tests, Heart,Heart Function Test,Test, Cardiac Function,Test, Heart Function,Tests, Cardiac Function,Tests, Heart Function
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

L Bajnok, and J Varga, and A Sztankay
August 1994, Kaku igaku. The Japanese journal of nuclear medicine,
L Bajnok, and J Varga, and A Sztankay
February 1994, Annals of nuclear medicine,
L Bajnok, and J Varga, and A Sztankay
January 1992, European journal of nuclear medicine,
L Bajnok, and J Varga, and A Sztankay
November 1994, Arquivos brasileiros de cardiologia,
L Bajnok, and J Varga, and A Sztankay
November 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
L Bajnok, and J Varga, and A Sztankay
January 2001, Revista clinica espanola,
L Bajnok, and J Varga, and A Sztankay
January 1995, Kaku igaku. The Japanese journal of nuclear medicine,
L Bajnok, and J Varga, and A Sztankay
July 1991, Seminars in nuclear medicine,
L Bajnok, and J Varga, and A Sztankay
February 1997, International journal of cardiac imaging,
L Bajnok, and J Varga, and A Sztankay
December 1991, Kaku igaku. The Japanese journal of nuclear medicine,
Copied contents to your clipboard!